Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers

Pursuant to a recommendation by the Nominating Committee, the board of directors (the "Board") of ImmuCell Corporation (the "Company") elected Mr. Bryan K. Gathagan as an independent director, effective June 16, 2023. In connection with Mr. Gathagan's election to the Board, the Board also appointed him as a member of its Audit Committee.

There are no related person transactions (or proposed related person transactions) with respect to Mr. Gathagan reportable under Item 5.02(d) of Form 8-K and Item 404(a) of Regulation S-K since the beginning of the Company's last fiscal year.

Mr. Gathagan will receive the same compensation as is paid to the Company's other non-employee directors, as described in the section entitled "Director Compensation" in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 28, 2023 (the "2023 Proxy Statement") which description is incorporated herein by reference.

On June 21, 2023, the Company issued a press release regarding Mr. Gathagan's election to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 5.07. Submission of Matters to a Vote of Security Holders

The 2023 Annual Meeting of Stockholders of the Company (the "2023 Annual Meeting") was held by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person event on Thursday, June 15, 2023, at 9:00 a.m. Eastern Time, for the following purposes:

1. To elect to one-year terms as Directors of the Company the six nominees listed


    in the 2023 Proxy Statement.

2. To approve a non-binding advisory resolution on the Company's executive


    compensation program.

3. To approve a non-binding advisory vote on whether to amend the Company's


    Common Stock Rights Plan extending its expiration date by one year to
    September 19, 2024.

4. To ratify the Audit Committee's selection of Wipfli LLP as the Independent

Registered Public Accounting Firm of the Company for the year ending December


    31, 2023.

At the 2023 Annual Meeting, there were present in person or by proxy 5,705,545 shares of the Company's common stock, representing more than 73% of the total outstanding eligible votes. The final voting results for each proposal are as follows:

1. To elect to one-year terms as Directors of the Company the nominees listed in


    the Company's Proxy Statement dated April 28, 2023:




                                                     Broker
                         For         Withheld       Non-votes
Gloria J. Basse        3,594,248        78,409       2,032,888
Michael F. Brigham     3,590,547        82,110       2,032,888
Bobbi Jo Brockmann     3,614,602        58,055       2,032,888
Steven T. Rosgen       3,592,944        79,713       2,032,888
David S. Tomsche       3,555,331       117,326       2,032,888
Paul R. Wainman        3,547,166       125,491       2,032,888

On the basis of this vote, each of the six nominees was elected to a one-year term as a Director of the Company.





                                       1

2. To approve a non-binding advisory resolution on the Company's executive


    compensation program:




    For         Against       Abstain       Broker Non-votes
  3,293,046       76,241       303,370           2,032,888

58% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution on the Company's executive compensation program was approved.

3. To approve a non-binding advisory vote on whether to amend the Company's

Common Stock Rights Plan extending its expiration by one year to September 19,


    2024:




    For           Against       Abstain       Broker Non-votes
  2,390,931       1,270,796       10,930           2,032,888

42% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution regarding the Company's Common Stock Rights Plan was not approved. However, since the approval of Proposal Three requires the approval of the holders of a majority of the shares of the Company's common stock represented at the meeting, abstentions, broker non-votes and votes against have the effect of a negative vote. Recognizing that there might be a substantial number of broker non-votes, the Company's Board of Directors, which has the authority to amend the Common Stock Rights Plan, stated in the 2023 Proxy Statement that it intends to be guided by the votes actually cast on this proposal in deciding whether to extend the expiration date of such plan by one year. Of the votes actually cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, the Board voted to extend the Common Stock Rights Plan by one year to September 19, 2024.

4. To ratify the Audit Committee's selection of Wipfli LLP as the Independent

Registered Public Accounting Firm of the Company for the year ending December


    31, 2023:




    For         Against      Abstain      Broker Non-votes
  5,687,633        9,343        8,569                 0

99.7% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the Audit Committee's selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2023 was ratified.

Item: 9.01 - Financial Statements and Exhibits





(d) Exhibits

The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed:





  99.1   Press Release of ImmuCell Corporation dated June 21, 2023.

  104  Cover Page Interactive Data File, formatted in Inline Extensible Business
       Reporting Language (iXBRL).




                                       2

© Edgar Online, source Glimpses